Study details cancer risk of Takeda diabetes pill

Thu May 31, 2012 6:30pm EDT

Related Topics

* Two years use of Actos doubles risk of bladder cancer

* Absolute risk still low, study finds

LONDON May 31 (Reuters) - Taking Takeda Pharmaceutical's diabetes drug Actos for more than two years doubles the risk of bladder cancer, although in absolute terms the risk is still low, researchers said on Thursday.

A study by Canadian researchers, published online by the British Medical Journal, quantified the risk by analysing the records of more than 115,000 British patients newly treated with diabetes drugs between 1988 and 2009.

They found that Actos use of two years or more was associated with 88 extra cases of bladder cancer per 100,000 person years. This rose to 137 extra cases among patients who had taken more than 28,000 milligrams of the drug.

Worries about a link between Actos and bladder cancer hit the headlines last year when U.S. and European regulators issued warnings about the risk, while deciding to keep the medicine on the market. The warnings hit sales of the drug.

In an editorial accompanying the new study, Dominique Hillaire-Buys and Jean-Luc Faillie from the Department of Medical Pharmacology and Toxicology in Montpellier, France, said the research would prompt questions about future use of Actos, which is known generically as pioglitazone.

"Prescribers who are ultimately responsible for therapeutic choices can legitimately question whether the benefit-risk ratio of pioglitazone is still acceptable for their patients with diabetes," they said.

Actos had peak sales of nearly $5 billion in the year to March 2010, but revenue has since declined, and Takeda faces generic competition as the drug's patents expire.

Takeda has previously said it is confident of the benefits of Actos in treating type 2 diabetes, and it continues to monitor the safety of all its medicines.

Actos belongs to the same drug class as GlaxoSmithKline's Avandia, which has been linked to heart problems but not bladder cancer.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
Your article was very informative. I have great concern about this class of drugs for the treatment of diabetes.

The shame about the Actos and bladder cancer case is that it’s hardly the first time this has happened. Many people were switched to Actos when the drug Avandia was found to cause heart attacks. My law firm has represented people who were harmed by both medications, and it’s a sad situation. Please visit and bookmark to keep up to date with the progress of this case.

Jun 06, 2012 2:30pm EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.